MedDataX Logo

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

NCT ID: NCT00051909

Last Updated: 2006-07-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-11-30

Study Completion Date

2003-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY451395

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have a clinical diagnosis of Alzheimer's Disease
* Must be at least 50 years of age
* Must fluently read and speak English
* Must have a reliable caregiver

Exclusion Criteria

* Has serious health problems other than Alzheimer's Disease
* Cannot swallow whole pills
* Has had a menstrual period in the last two years
* Takes insulin for diabetes
* Has taken Aricept, Reminyl, or Exelon in the last 5 weeks
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beverly Hills, California, United States

Site Status

Fresno, California, United States

Site Status

Boca Raton, Florida, United States

Site Status

Fort Lauderdale, Florida, United States

Site Status

Miami Beach, Florida, United States

Site Status

Boston, Massachusetts, United States

Site Status

Oklahoma City, Oklahoma, United States

Site Status

Tulsa, Oklahoma, United States

Site Status

Wichita Falls, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H6N-MC-LEAM

Identifier Type: -

Identifier Source: secondary_id

6764

Identifier Type: -

Identifier Source: org_study_id